Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

SECTION 1.2

Description of the concentration

1.On July 25, 2023, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (the “EUMR”). The proposed transaction involves the acquisition of joint control (within the meaning of Article 3(1)(b) EUMR) by funds controlled by affiliates of Warburg Pincus LLC (“Warburg Pincus”) and Advent International Corporation (“Advent”) over Baxter Pharmaceutical Solutions LLC and Baxter Oncology GmbH (“BPS”), by way of purchase of shares.

2.Warburg Pincus is a global private equity firm headquartered in New York, NY, United States. Its portfolio companies are active in a variety of sectors, including energy, financial services, healthcare and consumer, industrial and business services, and technology, media and telecommunications.

3.Advent is a private equity investor based in Boston, United States. Advent focuses on the acquisition of equity stakes and the management of investment funds in various sectors, including healthcare, industrial, technology, retail, consumer and leisure, and business and financial services.

4.BPS is Baxter International Inc.’s global pharmaceutical contract development and manufacturing business, with two facilities (located in the United States and in Germany). BPS provides Contract Development and Manufacturing Organization services for Finished Dose Pharmaceuticals.

Commission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË - Tel. +32 22991111